Authors
Mahat Taybi, Rhizlane Berrady, Samira El Fakir, Zineb Khammar, Noufissa Alami Drideb, Sarra Benmiloud, Laila Bouguenouch, Layla Tahiri Elousrouti, Laila Chbani, Nawal Hammas
Published in
Journal of hematopathology. Volume 19. Issue 1. Nov 17, 2026. Epub Nov 17, 2026.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma and is characterized by considerable biological and clinical heterogeneity. Despite advances in molecular profiling, readily available prognostic biomarkers remain essential for routine patient stratification. This study investigated the clinicopathological relevance of p53 expression in DLBCL and evaluated its association with Ki67 expression, cell-of-origin (COO) classification, molecular alterations, and clinical outcomes.
We conducted a retrospective study including 95 patients diagnosed with DLBCL at Hassan II University Hospital, Fez, Morocco, between 2010 and 2024. Clinicopathological characteristics, immunohistochemical expression of p53 and Ki67, COO classification according to Hans' algorithm, and molecular subtyping based on MYC, BCL2, and BCL6 rearrangements were assessed. Associations with treatment response, overall survival (OS), and event-free survival (EFS) were analyzed using univariate and multivariate statistical models.
High p53 expression (≥ 50%) was significantly associated with adverse clinicopathological characteristics, poorer treatment response, and inferior OS and EFS in univariate analyses. In contrast, Ki67 expression demonstrated limited prognostic value. Multivariable analysis identified the International Prognostic Index (IPI), p53 expression, COO classification, and molecular classification as independent predictors of both OS and EFS, whereas Ki67 did not retain independent prognostic significance. High p53 expression remained independently associated with inferior outcomes after adjustment for established clinical and biological risk factors.
Our findings support the clinicopathological relevance of p53 expression in DLBCL and confirm the prognostic importance of COO and molecular classification. The integration of immunohistochemical and molecular parameters may improve risk stratification and patient management, particularly in settings where comprehensive genomic profiling is not routinely available.
PMID:
43049816
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0